GLOW vs KLOW: How a Fourth Peptide Changes the Stack

GLOW and KLOW are vendor-formulated peptide blends that share three of four components. Both are sold for tissue repair, recovery, and skin or collagen support. Neither has FDA approval, neither has a published human RCT, and neither has clinical evidence that the specific ratio used is optimal for anything. Vendor convention drives the formulations.

GLOW composition (5:1:1 ratio):

• GHK-Cu 50 mg
• BPC-157 10 mg
• TB-500 10 mg
• Total: 70 mg per vial

KLOW composition (5:1:1:1 ratio):

• GHK-Cu 50 mg
• BPC-157 10 mg
• TB-500 10 mg
• KPV 10 mg
• Total: 80 mg per vial

The difference is KPV, the C-terminal tripeptide of alpha-MSH (Lys-Pro-Val). KPV's published evidence is dominated by preclinical work in inflammatory bowel disease and atopic dermatitis models, where it inhibits NF-kB signalling. Human RCT data is limited and mostly absent for the injectable dose ranges sold in the peptide market.

Why this comparison matters: most users buying KLOW pay the premium without understanding what the fourth peptide adds. The honest answer is "a mostly preclinical anti-inflammatory tripeptide aimed at gut and skin inflammation." That may or may not be worth the price difference depending on use case.

Composition:

• GLOW: 3 peptides, 70 mg total per vial.
• KLOW: 4 peptides, 80 mg total per vial. KPV is the only difference.

KPV's evidence base:

• KPV is the C-terminal tripeptide of alpha-MSH. The parent peptide (alpha-MSH) has documented anti-inflammatory effects mediated by melanocortin receptor binding. KPV retains some of the anti-inflammatory activity without the pigmentation or appetite effects of the full alpha-MSH molecule.
• Preclinical evidence is strongest in colitis models (DSS-induced colitis, IL-10 knockout colitis) and atopic dermatitis. KPV downregulates NF-kB signalling and reduces TNF-alpha and IL-6 in tissue.
• Human evidence is limited. Most published work is preclinical or in vitro. There is no published RCT of injectable KPV in healthy users or athletes for tissue repair indications.

Target use case:

• GLOW: general tissue repair, recovery, skin and collagen support. The GHK-Cu plus BPC-157 plus TB-500 combination is sold as a multi-mechanism repair blend.
• KLOW: the same plus an anti-inflammatory angle, marketed for users with concurrent gut or skin inflammation (IBD, IBS, rosacea, eczema). The KPV is the differentiator.

Copper load (identical):

• Both blends deliver 316 mcg of elemental copper per 2 mg GHK-Cu draw. The KPV in KLOW does not change the copper math. Cumulative copper over an 8-week daily cycle is the same: ~17.7 mg.

Reconstitution math:

• GLOW 70 mg in 2.5 mL = 28 mg/mL total concentration. Per-mg breakdown per mL: 20 GHK-Cu / 4 BPC-157 / 4 TB-500.
• KLOW 80 mg in 3 mL = 26.7 mg/mL total concentration. Per-mg breakdown per mL: 16.7 GHK-Cu / 3.3 BPC-157 / 3.3 TB-500 / 3.3 KPV.
• The standard 2 mg GHK-Cu anchor draw is 0.1 mL on GLOW (2.5 mL recon) or 0.12 mL on KLOW (3 mL recon). Adjust by reconstitution volume.

Cost:

• GLOW: typically USD $80-150 per vial from tier-1 vendors with COAs.
• KLOW: typically USD $90-170 per vial. The KPV adds modestly to cost.
• Both are vendor-blend premiums over running the components separately (separate peptides typically run 20-40% cheaper for the same total mass).

Storage stability:

• Same considerations for both. GHK-Cu is the limiting factor: light-sensitive, oxidises faster than the other peptides. Store reconstituted vials at 2-8 C, protected from light, use within 30 days. A colour shift from blue to teal indicates GHK-Cu degradation; the other peptides are also compromised when this happens.
• KPV does not extend or shorten the storage profile.

Choose GLOW if:

• Your goal is general tissue repair, recovery from training, or skin and collagen support.
• You have no significant gut or skin inflammation.
• You want the simpler, slightly cheaper blend.
• You are running it alongside TRT or AAS for adjunct recovery, not for a specific inflammatory condition.

Choose KLOW if:

• You have concurrent gut symptoms (IBD, IBS, post-antibiotic gut disruption) or skin inflammation (rosacea, eczema, atopic dermatitis) that you want to address while running the tissue repair stack.
• You are willing to pay the modest premium for an under-studied addition.
• You understand that KPV's evidence is mostly preclinical and the human dose-response is not characterised.

Choose neither (run separate components) if:

• You want independent titration of each peptide (e.g., pausing GHK-Cu alone if serum copper rises while continuing BPC-157 and TB-500).
• You want lower per-mg cost (20-40% savings for the same total mass from tier-1 vendors).
• You want QC distribution across three or four vendors rather than concentrated risk in one blend.

A note on KPV's marketing: vendors selling KLOW frequently overstate the evidence for KPV in healthy users. The strongest data is in preclinical colitis models. Extending that to "anti-inflammatory benefit for the average gym user" is a stretch. If you do not have a specific gut or skin inflammatory condition, the case for KLOW over GLOW is weak.